Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin added to surgical castration in newly diagnosed metastatic prostate cancer
PACTR202102664354163Completed
- Sponsor
- National Cancer Institute, Cairo University
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of rosuvastatin in prostate cancer (PCa) (2 arms), sponsored by National Cancer Institute, Cairo University. Started Jan 2019; status: completed.
02
Drugs
rosuvastatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on PACTR202102664354163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102664354163.